CoChat

The DOI matches its Crossref record; 68 of the 70 references it cites were found in a registry or an index.

USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression

Open access

Published version of a preprint

Abstract

Increasing evidence links deregulation of the ubiquitin-specific proteases 22 (USP22) deubitiquitylase to cancer development and progression in a select group of tumor types, but its specificity and underlying mechanisms of action are not well defined. Here we show that USP22 is a critical promoter of lethal tumor phenotypes that acts by modulating nuclear receptor and oncogenic signaling. In multiple xenograft models of human cancer, modeling of tumor-associated USP22 deregulation demonstrated that USP22 controls androgen receptor accumulation and signaling, and that it enhances expression of critical target genes coregulated by androgen receptor and MYC. USP22 not only reprogrammed androgen receptor function, but was sufficient to induce the transition to therapeutic resistance. Notably, in vivo depletion experiments revealed that USP22 is critical to maintain phenotypes associated with end-stage disease. This was a significant finding given clinical evidence that USP22 is highly deregulated in tumors, which have achieved therapeutic resistance. Taken together, our findings define USP22 as a critical effector of tumor progression, which drives lethal phenotypes, rationalizing this enzyme as an appealing therapeutic target to treat advanced disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-1954

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 127

Metadata

Authors
Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., Visakorpi, T., DeMarzo, A. M., McMahon, S. B., & Knudsen, K. E.
Affiliations
  • Johns Hopkins University (US)
  • Authors' Affiliations: Departments of 1Cancer Biology, 2Urology, 3Radiation Oncology, 4Pathology, and 5Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania; 6Sidney Kimmel Comprehensive Cancer Center; 7Department of Pathology, Johns Hopkins University, Baltimore, Maryland; and 8Institute of Biomedical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
Corresponding author
Knudsen, Karen E.
Venue
Cancer Research
Published
2014-01-01
Volume
74
Issue
1
Pages
272-286
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2162790141
Cited by
126
References
70
Citations by year
2026: 5 · 2025: 4 · 2024: 12 · 2023: 16 · 2022: 12 · 2021: 17 · 2020: 12 · 2019: 11 · 2018: 8 · 2017: 13 · 2016: 5 · 2015: 4 · 2014: 7
FWCI
2.39
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (R01CA159945, F31CA165475, F32CA156989, R01CA099996, R01CA164834, P30CA056036)
  • National Institute of Environmental Health Sciences (R01ES016675)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
USP22, deubiquitinase, androgen receptor, c-Myc, oncogenic signaling, treatment resistance, tumor progression, xenograft models, therapeutic target
MeSH terms
Adenocarcinoma, Animals, Disease Models, Animal, Humans, Male, Receptors, Androgen, Thiolester Hydrolases, Biomarkers, Tumor, Gene Expression, Gene Expression Regulation, Neoplastic, Mice, SCID, Disease Progression, Cell Culture Techniques, Ubiquitin Thiolesterase, Cell Line, Tumor, Proteasome Endopeptidase Complex, Mice, Androgen Receptor Antagonists, Prostatic Neoplasms, Castration-Resistant, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-1954
The paper
Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., Visakorpi, T., DeMarzo, A. M., McMahon, S. B., & Knudsen, K. E. (2014). USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-1954

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.